Psilocybin as a potential countermeasure to Toxoplasma gondii-induced behavioral modification: A hypothesis and proposed research framework
Abstract
Toxoplasma gondii is an obligate intracellular parasite that chronically infects approximately one-third of the global human population. Accumulating evidence links latent toxoplasmosis to alterations in host behavior, including changes in risk tolerance, reaction time, personality traits, and elevated rates of neuropsychiatric conditions including schizophrenia, bipolar disorder, and suicidal behavior. The parasite achieves these effects in part through manipulation of dopaminergic neurotransmission, as T. gondii tissue cysts contain the enzyme tyrosine hydroxylase and produce dopamine precursors. Despite the scale of infection and documented behavioral consequences, no therapeutic interventions currently target the behavioral sequelae of chronic toxoplasmosis. This paper proposes the hypothesis that psilocybin, a serotonergic psychedelic with documented effects on mood, anxiety, and personality, may counteract or attenuate behavioral modifications induced by chronic T. gondii infection through overlapping action on dopaminergic and serotonergic systems, anti-inflammatory effects, and promotion of neural plasticity. We present a detailed experimental framework for testing this hypothesis across animal models and human clinical populations, outline specific methodological considerations, and discuss the broader implications should this hypothesis be confirmed
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.